Citations

Clear

513 citation(s) found for "Ta, Casey".

Stool Microbiota, Metabolites, and Fecal Incontinence in Women
Arya, Lily A. , Kashyap, Purna , Carnes, Megan U., Mathur, Ravi, Richter, Holly E., Andy, U., Jelovsek, J. Eric, Siddiqui, Nazema Y., Morrow, Casey D. , Lefkowitz, Elliot J. , Pol, William J. Van Der, Broeckling, Corey, Carper, Benjamin, Jeney, Sarah E.S., Zyczynski, Halina M. , Dyer, Keisha Y., Carberry, Cassandra, Mazloomdoost, D., Network, for the NICHD Pelvic Floor Disorders, Arya, Lily A. , Carnes, Megan Ulmer , Mathur, Ravi , Richter, Holly E , Andy, Uduak Umoh , Pol, William J. Van Der, Broeckling, Corey D. , Carper, Benjamin , Jeney, Sarah E.S. , Carberry, Cassandra, Mazloomdoost, Donna , Gantz, Marie G.

Mayo Clinic

Urogynecology | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/spv.0000000000001885 | PMID 42240124 Get It

Importance Stool metabolites influencing gut motility and sensation may contribute to fecal incontinence (FI). Objective The objective of this study was to test whether FI is associated with higher levels of butyrate and Clostridiales taxa in stool. Study Design Stool metabolites and microbiota were compared between 96 women with FI and 42 controls. FI frequency and subtype (urgency vs insensible) were measured using a 14-day bowel diary, St. Mark’s score, and the Accidental Bowel Leakage questionnaire. Metabolite analysis included targeted analysis (8 short-chain fatty acids including butyrate, 17 bile acids, and 8 tryptophan derivatives) and untargeted analysis. Stool microbiota were characterized using 16S rRNA gene sequencing. Multivariable and exploratory multiomics factor analysis were performed with statistical significance defined as false discovery rate (FDR) ≤0.10. Results The FI group had a higher proportion of Bristol stool types 2 and 6 than controls ( P = 0.005). The mean number of leaks for the FI group was 1.7 ± 1.7 per day, 38% had urgency FI, and 39% had insensible FI. There was no significant difference between groups in butyrate levels and Clostridiales taxa. Multiomics analysis identified glycerolipids (monoacylglycerols and diacylglycerols) associated with FI (FDR = 0.08). In addition, insensible FI was associated with glycerolipids, long-chain saturated and monounsaturated fatty acids, phospholipids, and dipeptides (FDR = 0.08–0.09). The top weighted microbiota associated with these metabolites were Lachnospiraceae and Ruminococcaceae; however, these taxa were not directly associated with FI. Conclusion Butyrate and Clostridiales were not associated with FI. Novel stool metabolite signatures were identified, suggesting new biological pathways and potential therapeutic targets for FI.
Vascular endothelial growth factor receptor-1 (VEGFR-1) knock-down is protective against hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril -induced neuronal cell death: implications in AD pathogenesis
Li, Zonghua , Rachamala, Hari Krishnareddy, Castanedes-Casey, Monica, Kulkarni, Tanmay, Chakravarty, Trisha, Dutta, Shamit, Wang, Enfeng , Dickson, Dennis, Mukhopadhyay, Debabrata, Das, Pritam , Angom, Ramcharan Singh , Rachamala, Hari Krishnareddy, Castanedes‐Casey, Monica , Mukhopadhyay, Debabrata

Mayo Clinic

Frontiers in Neuroscience | May 29, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.3389/fnins.2026.1799391 | PMID 42292330 Get It

Introduction Recent transcriptome analysis has demonstrated increased expression of Vascular Endothelial Growth Factor receptor-1 (VEGFR-1/FLT1) and in AD brain. Increased expression of VEGFR1 and its ligand VEGFB were associated with a more rapid rate of cognitive decline, providing evidence of a potential link between increased VEGFR-1 expression in AD pathogenesis. In this study, we explored the potential role of VEGFR-1 expression in neurons on AD pathology. Methods To confirm VEGFR1 expression in AD brains, we first performed immunostaining in AD brain sections (AD - Braak stage V-VI, and normal controls - Braak 0-II). And to determine a potential detrimental role of neuronal VEGFR1 expression on AD associated pathologies, we exposed SH-SY5Y human neuroblastoma cells and mouse primary neurons to either hypoxia conditions (1%O 2 ) or 5 μ Aβ1-42 oligomers or fibrils for 24, 28 and 72hrs. Results In this study, we found preferential staining of VEGFR-1 in the neuropil and neuronal cell bodies both in AD and Control hippocampus and increased VEGFR-1 immunoreactivity in dystrophic neuritic processes in the vicinity of Thio-S positive amyloid plaques in AD brains. And treatment of SH-SY5Y human neuroblastoma cell line and mouse primary neurons, with either hypoxia conditions or Aβ1-42 oligomers, resulted in increased VEGFR-1 expression and cleaved caspase 3 activation, leading to neuronal toxicities/cell death. Similarly, treatment with Aβ1-42 fibrils also increased VEGFR-1 and cleaved caspase 3 protein levels in the SH-SY5Y cells whereas treatment with Aβ1-42 monomers had no effect on VEGFR-1 expression. In addition, we show that over-expression of VEGFR-1 intracellular domains in SH-SY5Y cells directly induced neuronal toxicities and importantly, siRNA-mediated knockdown of VEGFR-1 in neurons prevented the hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril-induced toxicities and cell death phenotypes. Treatment with either hypoxia or Aβ1-42 oligomers also reduced expression of cell survival genes including VEGFR-2 and Hippo pathway YAP1 and siRNA-mediated VEGFR-1 knockdown in the neurons normalized expression of both VEGFR-2 and YAP1. Using differential gene expression analysis, we demonstrated upregulation of several inflammatory/interferon-stimulated genes (ISGs) as well as increased expression of genes involved in activation of oxidative stress and cell death pathways in response to Aβ1-42 oligomers treatment in mouse primary neurons. And siRNA-mediated VEGFR-1 knockdown in the mouse primary neurons, reduced gene expression of both the ISGs and oxidative stress/cell death pathways in response to Aβ1-42 oligomer treatment. Discussion In summary, these results show that siRNA-mediated knockdown of VEGFR-1 in neurons significantly prevented hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril-induced cellular toxicities and cell death phenotypes, indicating a potential detrimental role of aberrant VEGFR-1 expression and signaling in response to AD associated pathologies.
MC240701: Decentralized pilot study of triple oral metronomic chemotherapy in recurrent/metastatic oral cavity cancer.
Baral, Binav, Nguyen, Anna C., Meyers, Jordan E., Fazer-Posorske, Casey, Lewis, Akeem Ronell, Zhao, Yujie, Chintakuntlawar, Ashish V., Asiedu, Gladys, Bayne, Harry E. Fuentes, Price, Katharine A. , Fazer-Posorske, Casey , Pritchett, Joshua C. , McGarrah, Patrick W. , Zhao, Yujie, Chintakuntlawar, Ashish V.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps6126 Get It

TPS6126 Background: Oral cavity cancers (OCC) are a rare subtype of head and neck cancer (HNC) with poor outcomes and limited second-line treatment options in the recurrent or metastatic (R/M) setting. Treatment-related morbidity and repeated local recurrences in OCC result in significant impairment of function and quality of life. Rural OCC patients comprise a sizable portion (50%) of our practice and are usually of lower socioeconomic status with lack of access to specialist care. They also have multiple barriers to treatment access and ancillary services, translating to poorer clinical outcomes. There is a critical need for effective and accessible therapies for R/M OCC in rural patients. Triple oral metronomic chemotherapy (TOMC) with Methotrexate, Erlotinib and Celecoxib (MEC) suppresses angiogenesis and activates antitumor microenvironment in HNC. Studies using TOMC in R/M OCC outside the US show reasonable efficacy (6-month OS 52.9%), better safety and lower cost compared to standard second line options. We hypothesize that a decentralized clinical trial with TOMC in R/M OCC is feasible, safe and effective in addition to being economical and accessible for rural patients. Methods: MC240701 is a single institution, open label, decentralized, single arm pilot study of MEC in patients with R/M OCC. Eligible pts must be ≥18 years old, have pathologically confirmed R/M OCC not amenable to curative-intent therapy, ECOG 0-2 and adequate organ function. At least 1 measurable lesion by RECIST 1.1 OR non-measurable disease (evident mucosal lesions, CNS/bone disease, lesions not meeting RECIST criteria) is permitted. Patients must have received standard first line immunotherapy with or without chemotherapy OR should be unable/unwilling to receive first line treatment. Key exclusion criteria include patients unable to take pills by mouth, serious medical co-morbidity or autoimmune disease, immunocompromised patients and other active malignancy. Primary endpoint is to demonstrate feasibility of decentralized clinical trials, secondary outcomes include overall response rate, progression free and overall survival and toxicity. Additional goals are to evaluate patient impact of decentralized treatment through surveys and interviews After initial screening and evaluation, patients are remotely consented and will receive study drugs by mail. All patients will receive the same treatment of Methotrexate 9mg/m 2 PO weekly, Erlotinib 150 mg PO daily, and Celecoxib 200 mg PO BID, each cycle will be 28 days. Treatment will continue until disease progression or treatment tolerance, study duration is for 2 years. All subsequent clinical and laboratory monitoring and response assessments (every 3 cycles) will be remotely performed or have an option for local testing. Enrollment began July 2025 and 4 out of planned 25 patients have been accrued. FDA IND:174540. Clinical trial information: NCT06997068 .
Phase 2 study of intratumoral oncolytic VV1 plus cemiplimab: Simon's stage 1 results from head and neck squamous cell carcinoma (HNSCC) cohort.
Powell, Steven , Nguyen, Anna C., Bayne, Harry E. Fuentes, Price, Katharine A. , Kern, Ryan, Fazer-Posorske, Casey, Anderson, D K, Baral, Binav, Boughton, Jennifer, Russell, Luke, Wiegert, Erol , Lowy, Israel , Seebach, Frank, Bexon, Alice, McGarrah, Patrick W. , Adamo, Daniel A. , Kern, Ryan , Fazer-Posorske, Casey , Boughton, Jen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e18026 Get It

e18026 Background: Immune checkpoint inhibitor (ICI) therapy is part of standard of care first-line therapy for recurrent or metastatic (R/M) HNSCC. However, less than 20% of patients (CPS ≥1) have an objective response to ICI monotherapy, and most tumors progress within ~3 months. We sought to improve the proportion of patients who benefit from a chemotherapy-free regimen by combining intratumoral (IT) VV1 oncolytic virus (VSV-IFNβ-NIS) injections with the anti-PD-1 antibody, cemiplimab. We report a pre-planned analysis of Simon's stage 1 results. Methods: We activated a phase 2 study testing the efficacy of first line IT VV1 plus cemiplimab in 1 st line patients with R/M HNSCC. A Simon's two-stage design was employed whereby 10 patients would be accrued in stage 1, and if 3 or more responses were observed, 12 additional patients would be accrued for stage 2. The primary endpoint was objective response rate (ORR) per investigator (RECIST 1.1). Eligible patients had untreated R/M HNSCC from primary oropharynx, oral cavity, hypopharynx, or larynx sites with CPS ≥1. Patients had to have at least one measurable lesion amenable to IT injection. Treatment comprised of IT injections to 1-5 lesions of oncolytic VV-1 virus and IV cemiplimab 350 mg on day 1, repeated every 21 days. Each lesion could be injected 3 times; a 4th injection was allowed if a partial response (PR) was achieved after 3 injections. Cemiplimab could be continued for up to 2 years until progression or unacceptable toxicity. Results: Patient and tumor characteristics, as well as efficacy and toxicity are summarized in the table below. Ten patients were treated at the time of Stage 1 analysis, with 3 showing a confirmed PR for ORR of 30%. Responder CPS scores were 45, 12 and 20%. Two of the responders subsequently showed progression after 6.2 and 9.9 months, the third has maintained PR at 7.7 months to date. Eight of 10 patients showed decrease in the sum of target lesion size (mean decrease of 16%; range -57 to 77%). One grade 2 event of ICI nephritis resolved with corticosteroid treatment. Conclusions: Three patients showed confirmed PR by RECIST 1.1 in Simon's stage 1, meeting criteria to proceed to Simon's stage 2. A total of 22 patients in the HNSCC will be enrolled. VV1 plus cemiplimab shows promise in first line R/M HNSCC based on these initial results. Clinical trial information: NCT04291105 . Patient demographics. N (treated) 10 Sex 20% female Median age (y) 60 (54 – 76) Oropharynx 7 HPV+ 7 Oral cavity 3 PD-L1 CPS median (range) 7.5 (1-45%) Locoregional injection 3 Distant injection 6 Local and distant injection 1 Best response (RECIST 1.1) PR 3 SD 5 PD 2 Adverse Events #pts any VV1/cemiplimab-related G3 AE 4 Lymphopenia 3 Elevated ALK 1
A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from the adenoid cystic cohort.
Price, Katharine A. , Foster, Nathan, Asmus, Erik, Bayne, Harry E. Fuentes, Fazer-Posorske, Casey, Meyers, Jordan E., Savvides, Panayiotis, Zhao, Yujie, Cooper, Anna C., Baral, Binav W., Burkett, Brian J., Dizdar, Nur, Lucien, Fabrice, Chintakuntlawar, Ashish V., Nathan, Foster, Asmus, Erik, Fazer-Posorske, Casey , Savvides, P. , McGarrah, Patrick W. , Burkett, Brian J., Whaley, Rumeal D. , Lucien, Fabrice , Chintakuntlawar, Ashish V.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 6123-6123

10.1200/jco.2026.44.16_suppl.6123 Get It

6123 Background: Pemetrexed (PTX) is safe and tolerable with responses reported in pts with R/M SGC. Given enhanced responses with PTX and pembrolizumab (PMB) for lung cancer, we hypothesized that PTX and PMB will have activity for SGC. Herein we present the efficacy results in pts with adenoid cystic carcinoma (ACC). Methods: MC200708 is a single arm phase II study of PTX and PMB in pts with R/M SGC (NCT04895735) with 2 cohorts: ACC (cohort A) and non-ACC (cohort B). Key eligibility criteria: ≥18 years, ECOG 0-1, measurable disease. Prior ICI and/or PTX was allowed. Key exclusion criteria: serious comorbidities, autoimmune disease and brain metastases. Simon’s 2-stage design was used for each cohort. Primary endpoint was overall response rate (ORR) for Cohort A but was amended to clinical benefit rate (CBR=SD+PR+CR) due to prolonged SD in several pts. Secondary endpoints: progression free survival (PFS), overall survival (OS), and toxicity. Exploratory analyses in Cohort A1 (post-amendment pts) included PSMA PET imaging and circulating PSMA extravesicles (EVs) as a biomarker. All pts received PTX 500 mg/m2 IV + PMB 200 mg IV q3 weeks until progression or treatment intolerance. Imaging was q3 cycles. Results: 20 pts (11 Cohort A + 9 Cohort A1) were enrolled from August 2021-Feb 2025. All 20 patients were eligible and received ≥ 1 cycle of treatment. Median age was 60.5 yrs, 50% male, performance status 0 (80%) or 1 (20%). 11 pts had no prior therapies (55.0%). The remaining pts had 1 (35%) or 2 (10%) prior lines of therapy. 75% of pts had no prior ICI. In Cohort A, the ORR was 0% (0 of 11). Cohort A1 met criteria for success based on CBR with 1 PR (12.5%) and 5 SD (62.5%) in the first 8 pts. For the whole cohort of 20 patients, the ORR was 5% (95% CI: 0.1-24.9) and the CBR rate was 75% (95% CI: 51-91) with 1 PR and 14 pts with SD. The duration of response for the 1 PR patient was 12.4 months. The median duration of response for the 15 pts with SD was 7.5 (2.0-29.7) months. 3 pts (15%) had PD and 2 pts (10%) went off prior to response assessment. Median cycles of treatment was 4 (2-30). In the 17 pts who discontinued, treatment was stopped in 9 (53%) for PD, 4 (23.5%) due to adverse events (AE), and 4 (23.5%) due to physician/patient preference. With a median follow-up of 14.5 months (1.5-39.2), the 1-year PFS rate is 52.1% (32.6 – 83.2%) and the OS rate is 82.1% (95% CI: 65.6 – 100%). The overall grade 3+ AE rate regardless of attribution was 80% (16/20). The most common grade 3 AEs were lymphocyte count decrease (40%), hypertension (20%), fatigue (10%), and pneumonitis (10%). 2 pts had a grade 4 AE (lymphocyte count decrease and thrombotic thrombocytopenic purpura). There were no treatment-related deaths. Analysis of correlative studies for Cohort A1 with PSMA imaging and EV biomarker ongoing. Conclusions: PTX and PMB has modest activity in pts with R/M ACC with CBR of 75% and prolonged benefit for some patients. Clinical trial information: NCT04895735 .
Dietary inorganic nitrate supplementation reduces central blood pressure, aortic stiffness, and blood pressure responsiveness in older adults
Seo, DongNyeuck , Bock, Joshua De , Hughes, William, Schneider, Aaron, Casey, Darren, Schneider, Aaron , Casey, Darren P.

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2301000 Get It

Aging is associated with increased aortic stiffness and exaggerated stress-induced blood pressure (BP) responsiveness, both of which contribute to the risk of cardiovascular disease. Supplementation with inorganic nitrate increases nitric oxide (NO) bioavailability and is a promising potential treatment to improve vascular function. While the acute effects of dietary inorganic nitrate supplementation on various measures of vascular function and BP have been demonstrated in several studies, the effects of increasing NO bioavailability through prolonged use (i.e. weeks) is unclear. Therefore, we tested the hypothesis that 4-weeks of inorganic nitrate supplementation will effectively increase NO bioavailability (as measured by plasma nitrate and nitrite) and reduce central BP, aortic stiffness, and BP responsiveness to a cold pressor test (CPT) in older adults. Thirteen older adults (67±3 years; 7 males and 6 females) completed a randomized, double-blind, placebo-controlled, crossover trial consisting of two 4-week supplementation periods (nitrate vs. placebo) separated by a 4-week washout. Central BP and carotid-femoral pulse wave velocity (cfPWV) were measured via applanation tonometry. Peripheral BP responses were assessed using beat-by-beat BP at baseline and during CPT. Plasma [nitrate] (40±24 to 76±46 µM, P< 0.01) and [nitrite] (289±94 to 413± 28 nM, P< 0.01) increased following inorganic nitrate supplementation, but remained unchanged after placebo ([nitrate] 39±20 to 39±16 µM, P=0.97; [nitrite] 303±108 to 302±87 nM, P=0.95). Four weeks of inorganic nitrate supplementation reduced resting measures of central systolic BP (cSBP; 116±12 to 113±10 mmHg, P< 0.05) and diastolic BP (cDBP; 79±8 to 74±6 mmHg, P< 0.05), as well as cfPWV (10.2±1.3 to 9.4±1.0 m/sec, P< 0.01), whereas no changes were observed following placebo (cSBP 112±10 to 115±10 mmHg; cDBP 75±7 to 78±7 mmHg; cfPWV 10.0±1.1 to 9.8±1.0 m/sec, P >0.05 for all). Additionally, the peak change (Δ from baseline) in peripheral SBP (28±10 to 23±6 mmHg, P< 0.05) and mean arterial pressure (MAP; 17±6 to 14±3 mmHg, P< 0.05) during the CPT were reduced following nitrate with no changes observed after placebo (SBP 25±8 to 26±12 mmHg, P=0.51; MAP 14±4 to 16±8 mmHg, P=0.19). Our findings demonstrate 4-weeks of inorganic dietary nitrate supplementation has favorable effects on central BP, aortic stiffness and BP responsiveness in older adults. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Hospital-Based Shootings in the US, 2000-2024
Wanberg, Erik J, Hooper, Chase C., Gerberi, Dana J., Clements, Casey M. , Wanberg, Erik J. , Gerberi, Danielle J , Mullan, Aidan F. , McGuire, Sarayna S.

Mayo Clinic

JAMA Network Open | May 4, 2026 | Volume: 9 | Issue: 5 | Pages: e2610552

10.1001/jamanetworkopen.2026.10552 | PMID 42081243 Get It

Importance Hospital-based shootings represent an extreme form of workplace violence, with notable consequences for staff, patients, and visitors. Despite growing concern, these events remain poorly understood. Objective To categorize hospital-based shootings from 2012 to 2024 and incorporate prior published events between 2000 and 2011 to examine trends in shootings over a 25-year span. Evidence Review Events in this systematic review of acute care hospital–based shootings in the US from January 1, 2012, through December 31, 2024, with subgroup analysis of previously published data trending shootings over 25 years (January 1, 2000, through December 31, 2024), were identified using EBSCO Regional Business News, ProQuest US Newsstream Collection, Gun Violence Archive, and Google News Search. Selected shooting events involved at least 1 injured person (a nonperpetrator or perpetrator) that occurred within or on the immediate property of the hospital. Findings A total of 327 news articles of unique hospital-based shooting events (5.2 per year per 1000 hospitals) were included from a review of 6658 articles, spanning 47 US states (94.0%). There was an overall incidence of 25.2 hospital-based shootings per year. Between 2012 and 2024, shootings increased by a mean (SD) of 1.7 (0.5) events per year, from 14 to 34 events (8.4% increase per year). Large hospitals accounted for the highest rate of shootings (258.1 events per 1000 hospitals). Events primarily occurred in urban settings (314 [96.0%]), and 161 (49.2%) occurred in the US South. Nearly one-third (105 [32.1%]) were potentially preventable by weapons screening. From 2000 to 2024, shootings increased by a mean (SD) of 1.1 (0.2) events per year, from 6 to 34 events (6.4% increase per year). A positive correlation was found in annual firearm fatalities in hospital settings and US firearms fatalities overall between 2012 and 2023 ( r = 0.42). Conclusions and Relevance This systematic review found that hospital-based shootings in the US have increased steadily over the past 25 years, representing an intersection between broader national trends in workplace and firearm violence. Large hospitals, those in the US South, and hospitals in urban communities are particularly at-risk settings. These findings underscore the need for hospital-specific prevention strategies, including consideration of weapons screening technology, alongside broader societal efforts to address rising firearm violence.
Abstract CT017: Neoadjuvant IL-1β and PD-1 inhibition in localized clear-cell renal cell carcinoma: Clinical and correlative analyses of the phase 1b SPARC-1 trial
McCann, Patrick J., Obradovic, Aleksandar, Ager, Casey R. , Rahiman, Chelsea L., Campbell, Kaitlyn R., Laplaca, Caroline, Johnston, Peyton C., Kim, Amanda, Gomez, Katherine, Manjrekar, Kriti Bagri , Stein, Mark N. , Drake, Charles G. , Runcie, Karie , Dallos, Matthew, McCann, Patrick J., Obradović, Aleksandar , Aggen, David H , Spina, Catherine S. , Rahiman, Chelsea L., Dallos, Matthew C. , McCann, Patrick J.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: CT017-CT017

10.1158/1538-7445.am2026-ct017 Get It

Abstract Background: Despite efficacy in metastatic clear cell renal cell carcinoma (ccRCC), immunotherapy currently has no role in the neoadjuvant setting. Suppressive tumor-associated macrophages (TAMs) are known to mediate resistance to immune checkpoint blockade (ICB) in ccRCC. In preclinical studies, IL-1β blockade reprograms TAMs toward an anti-tumor phenotype and promotes T cell activation, creating a tumor microenvironment (TME) more sensitive to ICB. To test this in patients, we conducted a correlative-rich neoadjuvant trial of IL-1β + PD-1 inhibition in localized ccRCC. Methods: SPARC-1 is a single-center, phase 1b study assessing the safety and feasibility of neoadjuvant canakinumab (αIL-1β) and spartalizumab (αPD-1) in patients with localized ccRCC (T1b-T4NanyM0 or TanyN1M0). All patients received 2 doses of canakinumab (300mg IV, Q4w) and spartalizumab (400mg IV, Q4w), 6 weeks (±7 days) prior to nephrectomy. The primary endpoint was safety and feasibility. Key secondary and exploratory endpoints included 12-month metastasis-free survival rate, pathologic response rate, and quantification of immune cell infiltration. To characterize immunologic reprogramming, fresh tumor specimens were collected at nephrectomy for single-cell RNA sequencing (scRNAseq) and multiparametric flow cytometry. Tissue from a treatment naïve cohort was collected for comparative analysis (n=16). Results: From August 15th, 2018, to January 30th, 2025, 14 patients were enrolled. There were no severe treatment-related adverse events (Grade ≥ 3) attributed to canakinumab or spartalizumab. At a median follow-up of 12.0 months (range, 6.3-12.0 months), the 12-month metastasis-free survival was 100%. Based on the ASSURE nomogram, the mean predicted 12-month recurrence risk was 16.7% (range, 4.7-46.5%). ScRNAseq revealed that treatment with αIL-1β + αPD-1 increased the frequency of TREM2+APOE+ TAMs (p=0.035), a population typically associated with immune suppression. However, these TAMs exhibited a phenotypic shift toward a less immunosuppressive state, with reduced IL-1β expression and increased CXCL9:SPP1 ratio, consistent with anti-tumor TAM polarization. Immune profiling revealed an increased CD8/CD4 T cell ratio (p=0.042) with modest enrichment of activated CD8+ T cells after treatment, supporting a more pro-inflammatory TME. Conclusions: The neoadjuvant combination of canakinumab (αIL-1β) and spartalizumab (αPD-1) is well-tolerated, feasible, and demonstrated promising clinical activity with no progression of disease observed in a localized ccRCC population at high risk of recurrence. Correlative analyses demonstrated that combined IL-1β and PD-1 blockade reprograms immunosuppressive TAMs, providing evidence that dual IL-1β and PD-1 inhibition can overcome myeloid-driven resistance in ccRCC. Clinical Trial Information: NCT04028245 Citation Format: Patrick J. McCann, Aleksandar Obradovic, Casey R. Ager, David H. Aggen, Catherine S. Spina, Chelsea L. Rahiman, Kaitlyn R. Campbell, Caroline Laplaca, Peyton C. Johnston, Amanda Kim, Katherine Gomez, Kriti Bagri Manjrekar, Mark N. Stein, Charles G. Drake, Karie Runcie, Matthew Dallos. Neoadjuvant IL-1β and PD-1 inhibition in localized clear-cell renal cell carcinoma: Clinical and correlative analyses of the phase 1b SPARC-1 trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr CT017.
Biochemical and Immunohistochemical Associations of TDP ‐43 and Cryptic RNA With Hippocampal and Amygdala Volumetrics in Alzheimer's Disease
Gatto, Rodolfo G. , Ghayal, Nikhil B , Ayuso, Virginia Estades, Jansen‐West, Karen , Dunmore, Judith A. , Song, Yuping , Yue, Mei, Cook, Casey , DeTure, Michael , Rawlinson, Bailey, Castanedes‐Casey, Monica, Jack, Clifford R., Petersen, Ronald C. , Petrucelli, Leonard, Whitwell, Jennifer L. , Prudencio, Mercedes , Josephs, Keith A. , Youseff, Hossam , Ghayal, Nikhil B , Estades Ayuso, Virginia , Rawlinson, Bailey D, Petersen, Ronald C , Dickson, Dennis W , Whitwell, Jennifer , Josephs, Keith A , Prudencio, Mercedes , Whitwell, Jennifer L , Youssef, Hossam , Castanedes‐Casey, Monica , Jack, Clifford R. , Dickson, Dennis W. , Petrucelli, Leonard

Mayo Clinic

Annals of Neurology | April 9, 2026 | Volume: 100 | Issue: 1 | Pages: 193-205

10.1002/ana.78223 | PMID 41952326 Get It

Objective Immunohistochemically (IHC) measured transactive response DNA‐binding protein 43 (TDP‐43) inclusions are observed in Alzheimer's disease (AD) and are associated with medial temporal lobe atrophy. Accumulation of cryptic exons occurs in AD in response to TDP‐43 pathology. We aimed to assess relationships between IHC and biochemically measured insoluble TDP‐43 and cryptic exons and assess associations with hippocampal and amygdala volume loss and atrophy rates on magnetic resonance imaging (MRI). Methods Eighty‐one neuropathologically diagnosed AD cases were analyzed. For biochemistry, insoluble TDP‐43 was quantified using a Meso‐scale discovery (MSD) immunoassay. IHC‐TDP burden was quantified with digital histopathology. Cryptic RNAs were assessed via quantitative real‐time polymerase chain reaction (qRT‐PCR). Thirty‐eight cases had serial brain MRI. Hippocampal and amygdala volumes were calculated using FreeSurfer. Regression models were used to investigate associations among IHC‐TDP‐43 status/burden, MSD‐TDP status/levels, cryptic RNAs, and hippocampal and amygdala volumes and atrophy rates. Results IHC‐TDP(+) cases exhibited elevated levels of MSD‐TDP and cryptic RNAs ( KCNQ2 , STMN2 , and UNC13A ) and increased MSD‐TDP levels were associated with increased cryptic RNA levels, in the hippocampus and amygdala. IHC‐TDP(+) cases had smaller hippocampal and amygdala volumes compared to IHC‐TDP(−) cases. MSD‐TDP(+) cases had smaller hippocampal volumes and faster amygdala rates of atrophy compared with MSD‐TDP(−) cases. Higher KCNQ2 and UNC13A levels were associated with smaller amygdala volumes. Interpretation MSD‐TDP level is a reliable surrogate for IHC‐based TDP‐43 status. Both TDP‐43 and cryptic RNA levels are associated with reduced medial temporal volumes, suggesting cryptic exons may be playing a role in brain volume loss in AD. ANN NEUROL 2026;100:193–205
Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer
Ganti, Ashwin , McGarrah, Patrick W. , Bayne, H. Fuentes, Fazer-Posorske, Casey , Baral, Binav, Ma, Daniel J., Neben-Wittich, M.A. , Wilson, Jessica , Moore, Eric J., Tasche, Kendall K. , Abel, Katie M. Van, Foster, Nathan R. , Price, Katharine A. , Daniel, J. , Fuentes, Harry E , Fuentes, Harry E , Baral, Binav , Ma, Daniel , Lester, Scott C. , Neben-Wittich, Michelle A, Wilson, Jessica M , Van Abel, Katie M, Price, Katharine A R , McGarrah, Patrick , Routman, David M. , Price, Daniel L. , Moore, Eric J. , Abel, Katie M. Van, Yin, Linda X.

Mayo Clinic

Viruses | April 8, 2026 | Volume: 18 | Issue: 4 | Pages: 446

10.3390/v18040446 | PMID 42043235 Get It

Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%; p = 0.5241). There were also no differences in hospitalizations for adverse events (38.9% in TPF vs. 40.5% in platinum doublet, p = 0.907) or recurrence (11.1% in TPF vs. 2.7% in platinum doublet, p = 0.198). The 5-year OS was 84.6% in the TPF group and 81.5% in the platinum doublet group (p = 0.581). Induction platinum doublet regimens offer comparable OS, response, and hospitalization rates to TPF in locally advanced HPV(+) OPSCC. Induction with a platinum doublet may be a viable de-escalation strategy for patients who are not candidates for TPF.